VICTORIA, BC – GuideStar Medical Devices (GuideStar) announces successful first clinical use of its flagship device, EpiZact. EpiZact, which was recently granted U.S. Food and Drug Administration (FDA) 510(k) clearance,… Read More
Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities Fusion shareholders to receive $21.00 per share in cash at closing plus a… Read More
Four $50,000 financial grants will be awarded to deserving Canadian public high schools to enhance scientific learning. Recipients can use the funds to renovate existing laboratory facilities, purchase new scientific equipment, develop… Read More
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS that represents approximately two percent of all ALS cases1 Health Canada regulatory decision on tofersen New Drug Submission expected in… Read More
This strategic addition underscores Eyam’s commitment to increase collaboration with global companies on their proven AI driven bioinformatics platform and innovative self-amplifying platforms to design and deliver vaccines and immunotherapeutics…. Read More
